TAYSHA GENE THERAPIES INC (TSHA) competitors & alternatives
Health Care · NASDAQ
TAYSHA GENE THERAPIES INC (TSHA)'s top competitors and alternatives — its most similar public companies — include REGENXBIO INC (RGNX), Ionis Pharmaceuticals (IONS), NEUROGENE INC (NGNE), MINERVA NEUROSCIENCES INC (NERV), OPUS GENETICS INC (IRD), Ultragenyx (RARE), ROCKET PHARMACEUTICALS INC (RCKT), ABEONA THERAPEUTICS INC (ABEO), ANAVEX LIFE SCIENCES CORP (AVXL), 4D MOLECULAR THERAPEUTICS INC (FDMT), PTC THERAPEUTICS INC (PTCT) and VOYAGER THERAPEUTICS INC (VYGR). These are TAYSHA GENE THERAPIES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top TSHA competitors & alternatives
-
REGENXBIO INCRGNXHealth Care
Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with…
$10.20 (as of 2026-07-22) · market cap $529M
-
Ionis PharmaceuticalsIONSHealth Care
Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic…
$54.01 (as of 2026-07-22) · market cap $8.8B
-
NEUROGENE INCNGNEHealth Care
Neurogene is a clinical-stage gene therapy company utilizing proprietary transgene regulation technology to develop treatments for rare, devastating…
$36.11 (as of 2026-07-22) · market cap $721M
-
MINERVA NEUROSCIENCES INCNERVHealth Care
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders, primarily focusing on…
$4.43 (as of 2026-07-22) · market cap $209M
-
OPUS GENETICS INCIRDHealth Care
Clinical-stage biopharmaceutical company developing AAV-based gene therapies to restore vision in patients with inherited retinal diseases.
$3.05 (as of 2026-07-22) · market cap $252M
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
ABEONA THERAPEUTICS INCABEOHealth Care
Abeona is a commercial-stage biopharmaceutical company that just received FDA approval for ZEVASKYN®, the first and only autologous cell-based gene therapy for…
$6.42 (as of 2026-07-22) · market cap $374M
-
ANAVEX LIFE SCIENCES CORPAVXLHealth Care
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple…
$2.55 (as of 2026-07-22) · market cap $234M
-
4D MOLECULAR THERAPEUTICS INCFDMTHealth Care
4D Molecular Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for ophthalmic and respiratory diseases using its proprietary…
$10.96 (as of 2026-07-22) · market cap $573M
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
VOYAGER THERAPEUTICS INCVYGRHealth Care
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while…
$3.10 (as of 2026-07-22) · market cap $187M
Not quite? Describe exactly what you want →
Peers are TAYSHA GENE THERAPIES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: TAYSHA GENE THERAPIES INC (TSHA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.